Terms of Use | ADCIRCA (tadalafil) tablets Once-daily treatment for PAH

TERMS OF USE AGREEMENT

This website may contain information about United Therapeutics Corporation, its subsidiaries and affiliates (collectively, "Company"), and/or one or more product marketed by Company. Access to and use of this website is subject to the following terms and conditions and all applicable laws. By accessing and using the website, you agree to be bound by and to comply with this Terms of Use Agreement without limitation or qualification and you acknowledge that it supersedes any other agreement between you and Company regarding this subject matter. If you do not agree with these Terms of Use, please exit and do not use the website. These terms of use may be revised by Company from time to time and you should therefore review them on your next visit to the website. Your continued use of the website following any such posting will be deemed as consent to the new notice, term or condition.

You may browse this website. You may download and print material from this website, provided that you retain all copyright and trademark notices contained in such materials. You may use such downloaded and printed materials for your own personal, non-commercial use. You may not use in any manner such materials for public or commercial purposes without Company's express written consent.
All product names, logos and service marks displayed on this website that are identified by "™" or "®" or that appear in type form different from that of the surrounding text are trademarks owned by or licensed to Company or our affiliates (collectively, "Trademarks"), unless otherwise identified as being owned by another entity. Nothing contained herein shall be construed as conferring by implication, estoppel or otherwise any license or right, either express or implied, under any patent or Trademark of Company or any third party. No use of any Trademark may be made without the prior written authorization of Company, except to identify the product or services of the company.
Company's products are available only by prescription from licensed health care professionals. Company does not provide medical advice or services.
You should assume that all content of the website is protected by copyright law unless otherwise noted and may not be used except as provided herein, or with the express written permission of Company. Except as expressly provided above, nothing contained herein shall be construed as conferring any license or right under any Company copyright.
You are prohibited from posting or transmitting to the website any unlawful, threatening, libelous, defamatory, obscene, inflammatory, pornographic or profane material or any material that could constitute or encourage conduct that would be considered a criminal offense, give rise to civil liability or would otherwise violate the law. Company will fully cooperate with any law enforcement authorities or court order requesting or directing Company to disclose the identity of anyone posting any such information or materials.

DISCLAIMER

COMPANY MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND OR NATURE WITH RESPECT TO ANY OF THE INFORMATION CONTAINED ON THIS WEBSITE. COMPANY DISCLAIMS ALL REPRESENTATIONS AND/OR WARRANTIES, EXPRESS OR IMPLIED, CREATED BY LAW, CONTRACT OR OTHERWISE, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, TITLE OR NONINFRINGEMENT.

In no event shall Company be liable for any damages of any kind or nature, including without limitation, direct, indirect, special, consequential or incidental damages arising from or in connection with the existence or use of the website and/or the information.

Important Safety Information for ADCIRCA^® (tadalafil) tablets

CONTRAINDICATIONS

Nitrates and Guanylate Cyclase (GC) Stimulators: Do not use ADCIRCA in patients taking medicines that contain nitrates or guanylate cyclase stimulators (such as riociguat), as the combination could cause a sudden, unsafe drop in blood pressure. Do not use nitrates within 48 hours of the last dose of ADCIRCA.

Hypersensitivity Reactions: Patients with a known serious hypersensitivity to tadalafil should not take ADCIRCA

WARNINGS AND PRECAUTIONS

Cardiovascular: Patients who experience anginal chest pain after taking ADCIRCA should seek immediate medical attention

Hypotension: Phosphodiesterase 5 inhibitors (PDE-5is), including tadalafil, have mild systemic vasodilatory properties that may result in transient decreases in blood pressure. Before prescribing ADCIRCA, carefully consider whether patients with underlying cardiovascular disease could be adversely affected by such actions.

Worsening Pulmonary Vascular Occlusive Disease: Pulmonary vasodilators may significantly worsen the cardiovascular status of patients with pulmonary veno-occlusive disease (PVOD) and administration of ADCIRCA to these patients is not recommended

Vision/Hearing: Patients who experience a sudden loss of vision in one or both eyes, which could be a sign of non-arteritic anterior ischemic optic neuropathy (NAION), or sudden decrease or loss of hearing after taking ADCIRCA should seek immediate medical attention

Prolonged Erection: In rare instances, men taking PDE-5is (including tadalafil) for ED reported an erection lasting more than four hours. Male patients who experience a prolonged erection should seek immediate medical attention

SPECIAL POPULATIONS AND POTENTIAL DRUG INTERACTIONS:

Special Populations (Pregnant or Expecting Pregnancy): Limited data from case series with tadalafil use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Pregnant women with untreated pulmonary arterial hypertension are at risk for heart failure, stroke, preterm delivery, and maternal and fetal death.

Special Populations (Renal or Hepatic Impairment): The use of ADCIRCA is not recommended for patients with severe renal or hepatic impairment. Please see Full Prescribing Information for dosing recommendations for patients with mild to moderate renal or hepatic impairment

Potential Drug Interactions: The use of ADCIRCA with alpha blockers, blood pressure medications, or alcohol may lower blood pressure significantly and may lead to symptomatic hypotension (light-headedness or fainting)

Potential Drug Interactions: Tadalafil is metabolized predominately by CYP3A in the liver. Use of ADCIRCA with potent CYP3A inhibitors, such as ketoconazole and itraconazole, should be avoided. For patients on ADCIRCA therapy that require treatment with ritonavir, ADCIRCA should be discontinued at least 24 hours prior to starting ritonavir. For patients on ritonavir therapy that require treatment with ADCIRCA, start ADCIRCA at 20 mg once a day. Use of ADCIRCA with potent inducers of CYP3A, such as rifampin, should be avoided

Potential Drug Interactions: ADCIRCA contains the same ingredient (tadalafil) as Cialis^®, which is used to treat erectile dysfunction (ED) and the signs and symptoms of benign prostatic hyperplasia (BPH). The safety and efficacy of combinations of ADCIRCA with Cialis or other PDE-5is have not been studied. Therefore, the use of such combinations is not recommended

ADVERSE REACTIONS

Adverse Reactions: The most common adverse event with ADCIRCA is headache (42% ADCIRCA vs 15% placebo). Other common adverse events (reported by ≥9% of patients on ADCIRCA and more frequent than placebo by 2%) include myalgia (14% vs 4%), nasopharyngitis (13% vs 7%), flushing (13% vs 2%), respiratory tract infection (13% vs 6%), extremity pain (11% vs 2%), nausea (11% vs 6%), back pain (10% vs 6%), dyspepsia (10% vs 2%), and nasal congestion (9% vs 1%)

ADC.ISI.HCP.SEP2020